Work

Phase 1 Dose-Escalation Trial of the Investigational Hedgehog (HH) Pathway Inhibitor Tak-441 in Patients with Advanced Solid Tumors

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33007-6

Authors: J.W. Goldman, S.G. Eckhardt, M. Borad, M. Hidalgo, D.P. Ryan, A. Parikh, S. Kuan, J. Yu, S. Stewart, L.S. Rosen

Institutions: Ronald Reagan UCLA Medical Center, UCLA Medical Center, University of Colorado Anschutz, Mayo Clinic in Arizona, Spanish National Cancer Research Centre, Massachusetts General Hospital, Takeda (United States), Takeda Oncology (United States)

Language: English

Topic: Hedgehog Signaling Pathway Studies

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2999456574

FWCI: 0.256

Cites:

Cited by: 2

Related to: 10